Skip to content

Comparison of the effect of Commiphora mukul and mefenamic acid on abnormal mensural bleeding

Comparison of the effect of Commiphora mukul capsule and mefenamic acid on menorrhagia: A-triple-blind randomized clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211125053177N1
Enrollment
60
Registered
2022-05-05
Start date
2022-07-11
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

menorrhagia. Excessive and frequent menstruation with regular cycle

Interventions

Intervention 1: The first intervention group receives a 250 g capsule containing commiphora mukul powder every 8 hours every month from the first to the fifth day of menstrual bleeding for 3 consecuti

Sponsors

Kerman University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 55 Years

Inclusion criteria

Inclusion criteria: Menorrhagia no history of known systemic or inflammatory pelvic diseases not pregnant Do not take certain medications not having a Pap smear and abnormal ultrasound not having a history of allergies to herbs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Menstrual bleeding volume and number of bleeding days based on Pictorial blood loss assessment chart (PBLAC)Hemoglobin level in CBC (Complete Blood Count) test. Timepoint: The seventh day of each cycle and if bleeding continues, the evaluation is done every week for up to three cycles. Method of measurement: Pictorial blood loss assessment chart (PBLAC), CBC (Complete Blood Count) laboratory test.

Secondary

MeasureTime frame
Quality of Life. Timepoint: Beginning and end of the study (after the end of the third menstrual cycle). Method of measurement: MQ Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAsma Ahmadzadeh Heshmati

Kerman University of Medical Sciences

a.ahmadzade1388@yahoo.com+98 34 3253 2275

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026